What Are Nanocarriers?

Nanocarriers are nanoscale vehicles, typically 10 to 500 nanometers in diameter, designed to encapsulate, protect, and deliver therapeutic, diagnostic, or imaging agents to specific biological targets. They are engineered to overcome the pharmacokinetic limitations of free drugs, including rapid clearance, nonspecific distribution, poor aqueous solubility, and susceptibility to enzymatic degradation. The concept emerged from liposome research in the 1960s, developed in Gerald Weissmann's and Alec Bangham's laboratories at the Weizmann Institute and Babraham Institute respectively, and has since expanded into a broad class of materials ranging from lipid assemblies to polymer matrices to inorganic nanostructures.

The design of a nanocarrier integrates considerations from colloidal chemistry, materials science, and pharmacology. Surface charge, hydrophilicity, particle size, and ligand density collectively govern how a carrier interacts with plasma proteins, evades phagocytic clearance, and accumulates at a target site. The enhanced permeability and retention (EPR) effect, by which long-circulating nanoparticles preferentially accumulate in tumor tissue through leaky vasculature, provided the original rationale for passive tumor targeting and underpins the clinical use of several approved nanomedicine products.

Types of Nanocarriers

The main structural classes of nanocarriers include liposomes, polymeric nanoparticles, dendrimers, inorganic nanoparticles, and lipid-polymer hybrids. Liposomes are bilayer vesicles with an aqueous core capable of encapsulating hydrophilic drugs and a lipid shell that accommodates hydrophobic drugs; Doxil, the first FDA-approved liposomal drug, has been in clinical use since 1995 for ovarian and breast cancer. Polymeric nanoparticles made from poly(lactic-co-glycolic acid) (PLGA) or polycaprolactone degrade through hydrolysis, releasing encapsulated molecules over days to weeks. Dendrimers are branched macromolecules with a defined number of terminal functional groups that allow precise loading of multiple drug molecules or targeting ligands. Research in PMC on nanocarrier usage for drug delivery in cancer therapy surveys these structural classes and compares their loading efficiencies, stability profiles, and routes to clinical translation.

Targeting Mechanisms

Nanocarriers can be functionalized with ligands, antibodies, peptides, or nucleic acid aptamers that bind receptors overexpressed on target cells, converting passive accumulation into active targeting. Folate receptors, HER2 receptors, and prostate-specific membrane antigen (PSMA) are among the most studied targets for oncology applications. Stimuli-responsive systems go further by triggering drug release only when the carrier reaches a particular microenvironment: low pH in the endosome, elevated glutathione in the cytoplasm, or elevated temperature from external hyperthermia. A review in Nature's Signal Transduction and Targeted Therapy on smart nanoparticles for cancer therapy describes how combining active targeting with stimuli-responsive release improves the ratio of therapeutic to toxic doses in preclinical tumor models.

Drug Loading and Release

The efficacy of a nanocarrier depends on its drug loading capacity and the kinetics of release at the target site. Loading efficiency is governed by the physicochemical compatibility between the drug and the carrier matrix: hydrophobic drugs associate readily with lipid bilayers and polymer cores, while charged hydrophilic molecules require electrostatic complexation or chemical conjugation. Release kinetics are engineered through matrix degradation rates, diffusion path lengths, and cross-link density. The Frontiers in Oncology review on lipid-based nanoparticles for cancer therapy covers how lipid composition, cholesterol content, and PEGylation affect release profiles and in vivo stability.

Applications

Nanocarriers have applications in a range of fields, including:

• Chemotherapy delivery to reduce systemic toxicity in cancer treatment
• mRNA and siRNA delivery for gene therapy and vaccination
• Targeted antibiotic delivery to treat intracellular bacterial infections
• Contrast agent transport for enhanced MRI and PET imaging
• Ocular drug delivery through topically applied nanoparticle formulations